Increased importin 13 activity is associated with the pathogenesis of pterygium.

Ke Xu, Tao Tao, Jing Jie, Xiaodong Lü, Xuezhi Li, Muhammad Aamer Mehmood, Hui He, Zhen Liu, Xinye Xiao, Jie Yang, Jian-xing Ma, Wei Li, Yueping Zhou, Zuguo LiuPubMed 2013

TL;DR

This study reveals that increased activity of importin 13 (IPO13), a nuclear transport protein, is linked to the development of pterygium, a common eye condition. The research suggests that IPO13 contributes to pterygium pathogenesis by influencing the expression of keratin 17 (K17) and the nuclear translocation of c-Jun, offering potential new therapeutic targets.

What Problem Does This Paper Address?

Pterygium, a fibrovascular growth on the eye's surface, affects millions worldwide and can lead to vision loss. Despite its prevalence, the underlying mechanisms driving its development remain largely unknown. Previous research has hinted at a connection between cell proliferation and pterygium, but specific molecular players and their roles are not well understood. This paper aims to elucidate the role of importin 13 (IPO13), a protein involved in nuclear import, in the pathogenesis of pterygium, exploring its interaction with other factors known to be involved in cell proliferation and disease progression.

Methods

The researchers employed a multi-pronged approach:

  • Immunohistochemistry: They examined tissue samples from patients with primary and recurrent pterygia, as well as normal conjunctiva, to visualize the distribution and levels of IPO13 and keratin 17 (K17).
  • Cell Culture: Pterygium epithelial cells (PECs) were cultured to study the effects of IPO13 manipulation.
  • Gene Manipulation: Lentivirus-mediated techniques were used to either silence (knockdown) or overexpress the IPO13 gene in PECs.
  • Western Blotting: This technique was used to quantify protein levels of IPO13, K17, and c-Jun in tissue samples and cultured cells.
  • Quantitative Real-Time PCR (qPCR): This method was used to measure the mRNA levels of K17, providing insights into gene expression.
  • Immunofluorescence Staining: This technique allowed for the visualization of protein localization within cells, particularly for assessing the colocalization of IPO13 and K17, and the nuclear translocation of c-Jun.
  • Subcellular Fractionation: This was used to separate nuclear and cytoplasmic components of cells to study the distribution of c-Jun.

Datasets

The study utilized tissue samples from:

  • 32 patients with pterygia (20 primary, 12 recurrent).
  • Normal conjunctival tissues obtained from an eye bank.

No new benchmarks were introduced; the focus was on analyzing existing human tissue samples and cultured cells.

Key Insights and Ideas

  • IPO13 is Upregulated in Pterygium: The study found significantly higher levels of IPO13 in pterygium epithelium compared to normal conjunctiva, particularly in the basal layer. This suggests IPO13 is not just present but actively involved in the disease.
  • IPO13 Drives Cell Proliferation: Manipulating IPO13 levels in cultured pterygium cells directly impacted their proliferation. Overexpression led to increased growth, while knockdown inhibited it, reinforcing IPO13's role in the hyperproliferative nature of pterygium.
  • IPO13 Interacts with K17: IPO13 was found to colocalize with K17, a protein implicated in epithelial proliferation and inflammation. Furthermore, IPO13 levels directly influenced K17 expression, with overexpression boosting K17 and knockdown reducing it. This points to a coordinated mechanism.
  • IPO13 Regulates c-Jun Nuclear Translocation: The research demonstrated that silencing IPO13 prevented c-Jun, a key transcription factor involved in cell proliferation and inflammation, from entering the nucleus. This suggests IPO13 acts as a gatekeeper for c-Jun's activity.

Key Results

  • Increased IPO13 Expression: Immunohistochemistry and western blotting confirmed significantly higher IPO13 levels in both primary and recurrent pterygium tissues compared to normal conjunctiva.
  • IPO13 Promotes PEC Proliferation: Overexpression of IPO13 in PECs led to a statistically significant increase in cell proliferation, while siRNA-mediated knockdown significantly inhibited it (p<0.001).
  • IPO13 Modulates K17 Expression: Silencing IPO13 reduced K17 mRNA and protein levels by approximately 50% and also led to obvious downregulation of K17 expression. Conversely, IPO13 overexpression upregulated K17 expression.
  • IPO13 Blocks c-Jun Nuclear Translocation: siRNA-IPO13 treatment resulted in cytoplasmic retention of c-Jun, while control siRNA did not affect its nuclear import. Western blot analysis confirmed this shift in c-Jun distribution.

Limitations and Future Work

  • Mechanism of IPO13-K17 Interaction: While colocalization and IPO13's influence on K17 expression were shown, the precise molecular mechanism by which IPO13 regulates K17 remains to be fully elucidated. The authors hypothesize it may be indirect, possibly through c-Jun.
  • Further Investigation of c-Jun's Role: While the study shows IPO13 affects c-Jun translocation, further research is needed to fully understand how this impacts pterygium pathogenesis.
  • Therapeutic Potential: The findings suggest that suppressing IPO13 could be a therapeutic strategy for pterygium. Future work could explore the efficacy and safety of such interventions.
  • Recurrent vs. Primary Pterygium Differences: The study noted higher IPO13 and K17 expression in recurrent pterygia, suggesting a more aggressive proliferation pattern. Further investigation is needed to understand the reasons behind this difference.

Summary updated

Abstract

We provided novel evidence that IPO13 may contribute to the pathogenesis of pterygium via modulation of K17 and c-Jun.
BibTeX
@inproceedings{xu2013increased,
  author = {Ke Xu and Tao Tao and Jing Jie and Xiaodong Lü and Xuezhi Li and Muhammad Aamer Mehmood and Hui He and Zhen Liu and Xinye Xiao and Jie Yang and Jian-xing Ma and Wei Li and Yueping Zhou and Zuguo Liu},
  title = {{Increased importin 13 activity is associated with the pathogenesis of pterygium.}},
  booktitle = {PubMed},
  year = {2013},
}
Figure